Hope Rugo· @hoperugo · X·· 1 天前评分70
正文 · 原文
Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026
317 浏览 · 14 赞 · 7 转发 · 1 回复
会议摘要
Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.org帖内回复
- Ziad Storyteller@AIZiadSaliba
@hoperugo @myESMO @OncoAlert What stands out to me is the move from single-pathway targeting to rational combinations, CDK4/6 with PI3K or AKT inhibition guided by ctDNA. Sequencing by clonal dynamics rather than line of therapy is where HR+ disease is heading #ESMO2026
来源：Hope Rugo · x.com